Heartland Cancer Research NCORP

NIH RePORTER · NIH · UG1 · $3,495,818 · view on reporter.nih.gov ↗

Abstract

The specific aims of the Heartland Cancer Research NCORP are to: To be the primary vector for delivering, implementing, and executing NCI approved cancer treatment clinical trials; cancer prevention, screening and control clinical trials; and Cancer Care Delivery Research clinical trials to a large Midwestern rural and urban population; Enhance Midwestern cancer care by providing convenient access for patients to a region-wide high standard of multidisciplinary integrated cancer care delivery; Participate in pilot studies for NCORP research bases and provide feedback on proposed trials. Participate in NCI-sponsored tissue acquisition and biobanking studies, including those related to the Cancer Moonshot initiative. Reach out to underserved and vulnerable populations across Illinois and Missouri to improve access to cancer clinical trials, state of the art care, and cancer prevention and early detection strategies; Coordinate with local and state agencies to leverage resources to improve state wide cancer education regarding cancer prevention, early detection, treatment and clinical trials; Improve cancer prevention, treatment, screening, and survivorship education for healthcare professionals throughout Illinois and Missouri. Educate healthcare providers across rural and urban Illinois and Missouri regarding cancer clinical trials and incorporation of new findings into daily patient care. Continue to recruit, train, and support new investigators and clinical research staff who share the vision and embrace the objectives of the Heartland NCORP. Explore and share best practices for improving the productivity of Heartland NCORP within an environment of limited resources.

Key facts

NIH application ID
10457972
Project number
5UG1CA189830-09
Recipient
DECATUR MEMORIAL HOSPITAL
Principal Investigator
Bryan Faller
Activity code
UG1
Funding institute
NIH
Fiscal year
2022
Award amount
$3,495,818
Award type
5
Project period
2014-08-01 → 2025-07-31